Multiple system atrophy, cerebellar type (MSA-c) is a form of multiple system atrophy (MSA) with predominant cerebellar features (gait and limb ataxia, oculomotor dysfunction, and dysarthria).
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding multiple system atrophy, cerebellar type is primarily due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the scope of systematic clinical studies and comprehensive research. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-c. Ongoing research may provide more insights in the future.
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are two orphan drugs designated for the treatment of multiple system atrophy, cerebellar type, which are in development: exidavnemab, a monoclonal antibody targeting alpha-synuclein, and verdiperstat, a drug aimed at neuroprotection. Additionally, there are four active clinical trials exploring various aspects of MSA-c. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20cerebellar%20type.
Actionable guidance for navigating care for multiple system atrophy, cerebellar type
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding multiple system atrophy, cerebellar type is primarily due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the scope of systematic clinical studies and comprehensive research. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-c. Ongoing research may provide more insights in the future.
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are two orphan drugs designated for the treatment of multiple system atrophy, cerebellar type, which are in development: exidavnemab, a monoclonal antibody targeting alpha-synuclein, and verdiperstat, a drug aimed at neuroprotection. Additionally, there are four active clinical trials exploring various aspects of MSA-c. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20cerebellar%20type.
Actionable guidance for navigating care for multiple system atrophy, cerebellar type
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding multiple system atrophy, cerebellar type is primarily due to its rarity, affecting fewer than 10 individuals per 100,000. This low prevalence restricts the scope of systematic clinical studies and comprehensive research. Additionally, the clinical features may overlap with other neurodegenerative disorders, complicating the characterization of MSA-c. Ongoing research may provide more insights in the future.
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Currently, there are two orphan drugs designated for the treatment of multiple system atrophy, cerebellar type, which are in development: exidavnemab, a monoclonal antibody targeting alpha-synuclein, and verdiperstat, a drug aimed at neuroprotection. Additionally, there are four active clinical trials exploring various aspects of MSA-c. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=multiple%20system%20atrophy%2C%20cerebellar%20type.
Actionable guidance for navigating care for multiple system atrophy, cerebellar type
To navigate your care effectively, seek a neurologist with expertise in movement disorders, particularly those familiar with multiple system atrophy. While there are currently no identified patient organizations specifically for MSA-c, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, inquire about participation in clinical trials, as this could provide access to cutting-edge treatments and contribute to the understanding of the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 5 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.